Nab-paclitaxel combined with oxaliplatin and S-1 as conversion therapy for advanced gastric adenocarcinoma.

被引：0
|
作者：
Ji, Ke
Bu, Zhaode
Yang, Heli
Wang, Zhenning
Liu, Funan
Liang, Pin
Dong, Yan
Zhang, Jie
Zhao, Qun
Liu, Yang
Ji, Jiafu
机构：
[1] Beijing Canc Hosp, Beijing, Peoples R China
[2] Peking Univ Canc Hosp, Minist Educ, Dept Gastrointestinal Surg, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
[3] China Med Univ, Affiliated Hosp 1, Shenyang, Peoples R China
[4] First Hosp China Med Univ, Shenyang, Peoples R China
[5] Dalian Med Univ, Affiliated Hosp 1, Dalian, Peoples R China
[6] Fourth Hosp Hebei Med Univ, Shijiazhuang, Peoples R China
[7] Fourth Hosp Hebei Med Univ, Hebei Tumor Hosp, Shijiazhuang, Hebei, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
343
引用
收藏
页码：343 / 343
页数：1
相关论文
共 50 条
  • [31] A phase 1 study of gemcitabine/nab-paclitaxel/S-1 (GAS) combination neoadjuvant chemotherapy for patients with locally advanced pancreatic adenocarcinoma
    Kondo, Naru
    Murakami, Yoshiaki
    Uemura, Kenichiro
    Sudo, Takeshi
    Hashimoto, Yasushi
    Nakagawa, Naoya
    Takahashi, Shinya
    Ohge, Hiroki
    Sueda, Taijiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (04) : 775 - 781
  • [32] Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma
    Li, Zhiwei
    Fan, Xiaona
    Jiang, Dan
    Li, Qingwei
    Liu, Chao
    Wang, Dan
    Li, Na
    Li, Hengzhen
    Chen, Zhuo
    Tang, Hongzhen
    Lou, Changjie
    Xu, Haitao
    Zhan, Chao
    Dong, Yuandi
    Ma, Zhigang
    Wang, Guangyu
    Zhang, Chunhui
    Lu, Haibo
    Zheng, Tongsen
    Zhang, Yanqiao
    ONCOLOGIST, 2024, 29 (11):
  • [33] Gemcitabine and nab-paclitaxel retreatment as a third-line therapy following second-line FOLFIRINOX for advanced pancreatic adenocarcinoma.
    Dean, Andrew Peter
    Das, Adarsh
    McNulty, Meabh
    Higgs, Domenic
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] A phase 1 study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers: TCOG T1216 study
    Tsai, Hui-Jen
    Yang, Shih-Hung
    Hsiao, Chin-Fu
    Kao, Hsiang-Fong
    Su, Yung-Yeh
    Shan, Yan-Shen
    Yen, Chia-Jui
    Du, Jeng-Shiun
    Hsu, Chiun
    Wu, I-Chen
    Chen, Li-Tzong
    ONCOLOGIST, 2024, 29 (10): : e1396 - e1405
  • [35] Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial
    Wen Zhang
    Chunxia Du
    Yongkun Sun
    Lin Yang
    Chengxu Cui
    Zhichao Jiang
    Chengfeng Wang
    Jinwang Wang
    Aiping Zhou
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 655 - 660
  • [36] Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial
    Zhang, Wen
    Du, Chunxia
    Sun, Yongkun
    Yang, Lin
    Cui, Chengxu
    Jiang, Zhichao
    Wang, Chengfeng
    Wang, Jinwang
    Zhou, Aiping
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (04) : 655 - 660
  • [37] A PHASE 1 STUDY OF GEMCITABINE / NAB-PACLITAXEL / S-1 (GAS) COMBINATION NEOADJUVANT CHEMOTHERAPY FOR PATIENTS WITH LOCALLY-ADVANCED PANCREATIC ADENOCARCINOMA
    Kondo, Naru
    Murakami, Yoshiaki
    Uemura, Kenichiro
    Sudo, Takeshi
    Hashimoto, Yasushi
    Nakagawa, Naoya
    Sueda, Taijiro
    GASTROENTEROLOGY, 2017, 152 (05) : S1250 - S1250
  • [38] First line gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma.
    Gulhati, Pat
    Prakash, Laura
    Katz, Matthew H. G.
    Wang, Xuemei
    Javle, Milind M.
    Shroff, Rachna T.
    Fogelman, David R.
    Lee, Jeffrey Edwin
    Tzeng, Ching-Wei David
    Lee, Jeffrey H.
    Weston, Brian
    Tamm, Eric P.
    Bhosale, Priya
    Koay, Eugene Jon
    Maitra, Anirban
    Wang, Huamin
    Wolff, Robert A.
    Varadhachary, Gauri R.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [39] A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer
    Nakayama, Norisuke
    Ishido, Kenji
    Chin, Keisho
    Nishimura, Ken
    Azuma, Mizutomo
    Matsusaka, Satoshi
    Inokuchi, Yasuhiro
    Tanabe, Satoshi
    Kumekawa, Yosuke
    Koizumi, Wasaburo
    GASTRIC CANCER, 2017, 20 (02) : 350 - 357
  • [40] Biologically optimized schedule of gemcitabine and nab-paclitaxel regimen in metastatic pancreatic adenocarcinoma.
    Abushahin, Laith I.
    Noonan, Anne M.
    Hays, John L.
    Malalur, Pannaga G.
    Manne, Ashish
    Jin, Ning
    Mittra, Arjun
    Elkhatib, Rifat T.
    Roychowdhury, Sameek
    Williams, Terence Marques
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345